Skip to contentD
DNA X, Inc.
D
SONMDNA X, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$13.43M$13.43Mderived−44.3% vs Q4 2022 Net Income-$1.35M-$1.35MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DNA X, Inc. · CIK 1178697 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$5,120,000+30.2% Operating Incomederived-$1,255,000N/M Operating Cash Flowderived-$351,000N/M Free Cash Flowderived-$363,000N/M Margins · derivedGross margin38.1%+21.8 pt vs Q4 2022
Operating margin-9.3%−5.0 pt vs Q4 2022
Net margin-10.1%−5.8 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 27, 2024 · 87 d after period end